Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder Cancer

Stephen A. Boorjian, MD
Published: Wednesday, Apr 01, 2020



Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

In a phase III trial (NCT02773849), investigators evaluated intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive NMIBC. The complete response (CR) rate at any time during therapy in patients with carcinoma in situ served as the primary endpoint of the study, says Boorjian.

Among 103 patients with carcinoma in situ, 55 (53.4%) achieved CR, all by the third month of treatment. Of these 55 patients, 25 (45.5%) remained free of high-grade recurrence at 1 year, demonstrating the durability of these responses, concludes Boorjian.
SELECTED
LANGUAGE


Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

In a phase III trial (NCT02773849), investigators evaluated intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive NMIBC. The complete response (CR) rate at any time during therapy in patients with carcinoma in situ served as the primary endpoint of the study, says Boorjian.

Among 103 patients with carcinoma in situ, 55 (53.4%) achieved CR, all by the third month of treatment. Of these 55 patients, 25 (45.5%) remained free of high-grade recurrence at 1 year, demonstrating the durability of these responses, concludes Boorjian.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x